BACKGROUND: The prevalence of vitamin D deficiency and its consequences on bone in pediatric bone fragility disorders is not well characterized. In the present study, we evaluated determinants of vitamin D status in children and adolescents with osteogenesis imperfecta (OI) and assessed the relationship between 25-hydroxyvitamin D (25OH D) serum concentrations and lumbar spine areal bone mineral density (LS-aBMD). MATERIALS AND METHODS: This retrospective cross-sectional study comprised 315 patients with a diagnosis of OI type I, III, or IV (aged 1.1-17.9 yr; 161 girls) who had not received bisphosphonate treatment at the time of 25OH D analysis. In 282 patients (90%), LS-aBMD measurements were available at the same time. RESULTS: Serum concentrations of 25OH D ranged from 14 to 133 nmol/liter and were less than 50 nmol/liter in 86 patients (27%). Regression analysis revealed that age (P < 0.001), season (P < 0.001), and OI severity (P = 0.048), but not gender, were significant independent predictive factors of 25OH D levels. Serum 25OH D concentrations were negatively correlated with serum PTH levels (P = 0.003) and urinary cross-linked N-telopeptides of type I collagen to creatinine ratios (P = 0.005). Serum 25OH D levels were positively associated (P = 0.02) with LS-aBMD z-scores after accounting for OI severity, age, and gender. CONCLUSION: Serum 25OH D levels are positively associated with LS-aBMD z-scores in children and adolescents with OI types I, III, and IV.
BACKGROUND: The prevalence of vitamin Ddeficiency and its consequences on bone in pediatric bone fragility disorders is not well characterized. In the present study, we evaluated determinants of vitamin D status in children and adolescents with osteogenesis imperfecta (OI) and assessed the relationship between 25-hydroxyvitamin D (25OH D) serum concentrations and lumbar spine areal bone mineral density (LS-aBMD). MATERIALS AND METHODS: This retrospective cross-sectional study comprised 315 patients with a diagnosis of OI type I, III, or IV (aged 1.1-17.9 yr; 161 girls) who had not received bisphosphonate treatment at the time of 25OH D analysis. In 282 patients (90%), LS-aBMD measurements were available at the same time. RESULTS: Serum concentrations of 25OH D ranged from 14 to 133 nmol/liter and were less than 50 nmol/liter in 86 patients (27%). Regression analysis revealed that age (P < 0.001), season (P < 0.001), and OI severity (P = 0.048), but not gender, were significant independent predictive factors of 25OH D levels. Serum 25OH D concentrations were negatively correlated with serum PTH levels (P = 0.003) and urinary cross-linked N-telopeptides of type I collagen to creatinine ratios (P = 0.005). Serum 25OH D levels were positively associated (P = 0.02) with LS-aBMD z-scores after accounting for OI severity, age, and gender. CONCLUSION: Serum 25OH D levels are positively associated with LS-aBMD z-scores in children and adolescents with OI types I, III, and IV.